clinical trial · NCT06474455
A Phase IB/II Clinical Study of SHR-9839 for Injection Combined With Other Anti-tumor Therapies in Patients With Advanced Solid Tumors
Shanghai Hengrui Pharmaceutical Co., Ltd.·phase2·recruiting·n = 156
Advanced Solid TumorsSHR-9839 for InjectionSHR-A1921 for InjectionSHR-A2009 for InjectionAlmonertinib Mesilate TabletsPemetrexed Disodium for InjectionCarboplatin for injectionPaclitaxel injectionAdebrelimab Injection
brief summary
This study is an open-label, multicenter Phase IB/II clinical trial to evaluate the safety, tolerability and efficacy of SHR-9839 for injection in combination with other antitumor therapies in patients with advanced solid tumors.
started
Jun 2, 2024
primary completion
Jun 1, 2026
completion
Jun 1, 2027
last updated
May 5, 2026
official title
A Phase IB/II, Open-Label, Multicentre Clinical Study to Evaluate the Safety, Tolerability and Efficacy of SHR-9839 for Injection in Combination With Other Therapies in Patients With Advanced Solid Tumors
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol